Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 65 entries
Sorted by: Best Match Show Resources per page
Germline whole exome sequencing and large-scale replication identifies .

Oncotarget

Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP.
PMID: 28881617
Oncotarget. 2017 Mar 03;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 01.

We analyzed whole exome sequencing data in germline DNA from 412 high grade serous ovarian cancer (HGSOC) cases from The Cancer Genome Atlas Project and identified 5,517 genes harboring a predicted deleterious germline coding mutation in at least one...

Cite
Dicks E, Song H, Ramus SJ, et al. Germline whole exome sequencing and large-scale replication identifies . Oncotarget. 2017;8(31):50930-50940doi: 10.18632/oncotarget.15871.
Dicks, E., Song, H., Ramus, S. J., Oudenhove, E. V., Tyrer, J. P., Intermaggio, M. P., Kar, S., Harrington, P., Bowtell, D. D., Group, A. S., Cicek, M. S., Cunningham, J. M., Fridley, B. L., Alsop, J., Jimenez-Linan, M., Piskorz, A., Goranova, T., Kent, E., Siddiqui, N., Paul, J., Crawford, R., Poblete, S., Lele, S., Sucheston-Campbell, L., Moysich, K. B., Sieh, W., McGuire, V., Lester, J., Odunsi, K., Whittemore, A. S., Bogdanova, N., Dürst, M., Hillemanns, P., Karlan, B. Y., Gentry-Maharaj, A., Menon, U., Tischkowitz, M., Levine, D., Brenton, J. D., Dörk, T., Goode, E. L., Gayther, S. A., & Pharoah, D. P. P. (2017). Germline whole exome sequencing and large-scale replication identifies . Oncotarget, 8(31), 50930-50940. https://doi.org/10.18632/oncotarget.15871
Dicks, Ed, et al. "Germline whole exome sequencing and large-scale replication identifies ." Oncotarget vol. 8,31 (2017): 50930-50940. doi: https://doi.org/10.18632/oncotarget.15871
Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP. Germline whole exome sequencing and large-scale replication identifies . Oncotarget. 2017 Mar 03;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 01. PMID: 28881617; PMCID: PMC5584218.
Copy Download .nbib Format: NLM
Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment.

Frontiers in oncology

Chien J, Kuang R, Landen C, Shridhar V.
PMID: 24069583
Front Oncol. 2013 Sep 24;3:251. doi: 10.3389/fonc.2013.00251.

Despite several advances in the understanding of ovarian cancer pathobiology, in terms of driver genetic alterations in high-grade serous cancer, histologic heterogeneity of epithelial ovarian cancer, cell-of-origin for ovarian cancer, the survival rate from ovarian cancer is disappointingly low...

Cite
Chien J, Kuang R, Landen C, et al. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol. 2013;3:251doi: 10.3389/fonc.2013.00251.
Chien, J., Kuang, R., Landen, C., & Shridhar, V. (2013). Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Frontiers in oncology, 3251. https://doi.org/10.3389/fonc.2013.00251
Chien, Jeremy, et al. "Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment." Frontiers in oncology vol. 3 (2013): 251. doi: https://doi.org/10.3389/fonc.2013.00251
Chien J, Kuang R, Landen C, Shridhar V. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol. 2013 Sep 24;3:251. doi: 10.3389/fonc.2013.00251. PMID: 24069583; PMCID: PMC3781360.
Copy Download .nbib Format: NLM
Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR.

Oncotarget

Gill SE, Zhang Q, Keeney GL, Cliby WA, Weroha SJ.
PMID: 29156714
Oncotarget. 2017 Jul 27;8(49):85214-85223. doi: 10.18632/oncotarget.19620. eCollection 2017 Oct 17.

MISIIR is a potential target for ovarian cancer (OC) therapy due to its tissue-specific pattern of expression. 3C23K is a novel therapeutic monoclonal anti-MISIIR antibody designed to recruit effector cells and promote cell death through ADCC (antibody dependent cell-mediated...

Cite
Gill SE, Zhang Q, Keeney GL, et al. Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR. Oncotarget. 2017;8(49):85214-85223doi: 10.18632/oncotarget.19620.
Gill, S. E., Zhang, Q., Keeney, G. L., Cliby, W. A., & Weroha, S. J. (2017). Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR. Oncotarget, 8(49), 85214-85223. https://doi.org/10.18632/oncotarget.19620
Gill, Sarah E, et al. "Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR." Oncotarget vol. 8,49 (2017): 85214-85223. doi: https://doi.org/10.18632/oncotarget.19620
Gill SE, Zhang Q, Keeney GL, Cliby WA, Weroha SJ. Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR. Oncotarget. 2017 Jul 27;8(49):85214-85223. doi: 10.18632/oncotarget.19620. eCollection 2017 Oct 17. PMID: 29156714; PMCID: PMC5689604.
Copy Download .nbib Format: NLM
Whole genome amplification of single epithelial cells dissociated from snap-frozen tissue samples in microfluidic platform.

Biomicrofluidics

Liu Y, Yao J, Walther-Antonio M.
PMID: 31149320
Biomicrofluidics. 2019 May 15;13(3):034109. doi: 10.1063/1.5090235. eCollection 2019 May.

Single cell sequencing is a technology capable of analyzing the genome of a single cell within a population. This technology is mostly integrated with microfluidics for precise cell manipulation and fluid handling. So far, most of the microfluidic-based single...

Cite
Liu Y, Yao J, Walther-Antonio M. Whole genome amplification of single epithelial cells dissociated from snap-frozen tissue samples in microfluidic platform. Biomicrofluidics. 2019;13(3):034109doi: 10.1063/1.5090235.
Liu, Y., Yao, J., & Walther-Antonio, M. (2019). Whole genome amplification of single epithelial cells dissociated from snap-frozen tissue samples in microfluidic platform. Biomicrofluidics, 13(3), 034109. https://doi.org/10.1063/1.5090235
Liu, Yuguang, et al. "Whole genome amplification of single epithelial cells dissociated from snap-frozen tissue samples in microfluidic platform." Biomicrofluidics vol. 13,3 (2019): 034109. doi: https://doi.org/10.1063/1.5090235
Liu Y, Yao J, Walther-Antonio M. Whole genome amplification of single epithelial cells dissociated from snap-frozen tissue samples in microfluidic platform. Biomicrofluidics. 2019 May 15;13(3):034109. doi: 10.1063/1.5090235. eCollection 2019 May. PMID: 31149320; PMCID: PMC6520095.
Copy Download .nbib Format: NLM
Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.

Cell death & disease

Liu D, Hou X, Wu W, Zanfagnin V, Li Y, Correia C, Zhao Z, Zhao C, Liu Z, Zhang T, Fang Z, Wang H, Xu C, Weroha SJ, Kaufmann SH, Dai H.
PMID: 34385422
Cell Death Dis. 2021 Aug 12;12(8):789. doi: 10.1038/s41419-021-04073-0.

We previously found that preformed complexes of BAK with antiapoptotic BCL2 proteins predict BH3 mimetic sensitivities in lymphohematopoietic cells. These complexes have not previously been examined in solid tumors or in the context of conventional anticancer drugs. Here we...

Cite
Liu D, Hou X, Wu W, et al. Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Cell Death Dis. 2021;12(8):789doi: 10.1038/s41419-021-04073-0.
Liu, D., Hou, X., Wu, W., Zanfagnin, V., Li, Y., Correia, C., Zhao, Z., Zhao, C., Liu, Z., Zhang, T., Fang, Z., Wang, H., Xu, C., Weroha, S. J., Kaufmann, S. H., & Dai, H. (2021). Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Cell death & disease, 12(8), 789. https://doi.org/10.1038/s41419-021-04073-0
Liu, Dongyan, et al. "Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer." Cell death & disease vol. 12,8 (2021): 789. doi: https://doi.org/10.1038/s41419-021-04073-0
Liu D, Hou X, Wu W, Zanfagnin V, Li Y, Correia C, Zhao Z, Zhao C, Liu Z, Zhang T, Fang Z, Wang H, Xu C, Weroha SJ, Kaufmann SH, Dai H. Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Cell Death Dis. 2021 Aug 12;12(8):789. doi: 10.1038/s41419-021-04073-0. PMID: 34385422; PMCID: PMC8361168.
Copy Download .nbib Format: NLM
Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments.

Cancer research

Yoo KH, Tang JJ, Rashid MA, Cho CH, Corujo-Ramirez A, Choi J, Bae MG, Brogren D, Hawse JR, Hou X, Weroha SJ, Oliveros A, Kirkeby LA, Baur JA, Jang MH.
PMID: 33771896
Cancer Res. 2021 Jul 01;81(13):3727-3737. doi: 10.1158/0008-5472.CAN-20-3290. Epub 2021 Mar 26.

Chemotherapy-induced cognitive impairment (CICI) is often reported as a neurotoxic side effect of chemotherapy. Although CICI has emerged as a significant medical problem, meaningful treatments are not currently available due to a lack of mechanistic understanding underlying CICI pathophysiology....

Cite
Yoo KH, Tang JJ, Rashid MA, et al. Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. Cancer Res. 2021;81(13):3727-3737doi: 10.1158/0008-5472.CAN-20-3290.
Yoo, K. H., Tang, J. J., Rashid, M. A., Cho, C. H., Corujo-Ramirez, A., Choi, J., Bae, M. G., Brogren, D., Hawse, J. R., Hou, X., Weroha, S. J., Oliveros, A., Kirkeby, L. A., Baur, J. A., & Jang, M. H. (2021). Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. Cancer research, 81(13), 3727-3737. https://doi.org/10.1158/0008-5472.CAN-20-3290
Yoo, Ki Hyun, et al. "Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments." Cancer research vol. 81,13 (2021): 3727-3737. doi: https://doi.org/10.1158/0008-5472.CAN-20-3290
Yoo KH, Tang JJ, Rashid MA, Cho CH, Corujo-Ramirez A, Choi J, Bae MG, Brogren D, Hawse JR, Hou X, Weroha SJ, Oliveros A, Kirkeby LA, Baur JA, Jang MH. Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. Cancer Res. 2021 Jul 01;81(13):3727-3737. doi: 10.1158/0008-5472.CAN-20-3290. Epub 2021 Mar 26. PMID: 33771896; PMCID: PMC8277702.
Copy Download .nbib Format: NLM
The Trifecta of Single-Cell, Systems-Biology, and Machine-Learning Approaches.

Genes

Weiskittel TM, Correia C, Yu GT, Ung CY, Kaufmann SH, Billadeau DD, Li H.
PMID: 34356114
Genes (Basel). 2021 Jul 20;12(7). doi: 10.3390/genes12071098.

Together, single-cell technologies and systems biology have been used to investigate previously unanswerable questions in biomedicine with unparalleled detail. Despite these advances, gaps in analytical capacity remain. Machine learning, which has revolutionized biomedical imaging analysis, drug discovery, and systems...

Cite
Weiskittel TM, Correia C, Yu GT, et al. The Trifecta of Single-Cell, Systems-Biology, and Machine-Learning Approaches. Genes (Basel). 2021;12(7)doi: 10.3390/genes12071098.
Weiskittel, T. M., Correia, C., Yu, G. T., Ung, C. Y., Kaufmann, S. H., Billadeau, D. D., & Li, H. (2021). The Trifecta of Single-Cell, Systems-Biology, and Machine-Learning Approaches. Genes, 12(7), . https://doi.org/10.3390/genes12071098
Weiskittel, Taylor M, et al. "The Trifecta of Single-Cell, Systems-Biology, and Machine-Learning Approaches." Genes vol. 12,7 (2021). doi: https://doi.org/10.3390/genes12071098
Weiskittel TM, Correia C, Yu GT, Ung CY, Kaufmann SH, Billadeau DD, Li H. The Trifecta of Single-Cell, Systems-Biology, and Machine-Learning Approaches. Genes (Basel). 2021 Jul 20;12(7). doi: 10.3390/genes12071098. PMID: 34356114; PMCID: PMC8306972.
Copy Download .nbib Format: NLM
CHFR and Paclitaxel Sensitivity of Ovarian Cancer.

Cancers

Wahner Hendrickson AE, Visscher DW, Hou X, Goergen KM, Atkinson HJ, Beito TG, Negron V, Lingle WL, Bruzek AK, Hurley RM, Wagner JM, Flatten KS, Peterson KL, Schneider PA, Larson MC, Maurer MJ, Kalli KR, Oberg AL, Weroha SJ, Kaufmann SH.
PMID: 34885153
Cancers (Basel). 2021 Nov 30;13(23). doi: 10.3390/cancers13236043.

The poly(ADP-ribose) binding protein CHFR regulates cellular responses to mitotic stress. The deubiquitinase UBC13, which regulates CHFR levels, has been associated with better overall survival in paclitaxel-treated ovarian cancer. Despite the extensive use of taxanes in the treatment of...

Cite
Wahner Hendrickson AE, Visscher DW, Hou X, et al. CHFR and Paclitaxel Sensitivity of Ovarian Cancer. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13236043.
Wahner Hendrickson, A. E., Visscher, D. W., Hou, X., Goergen, K. M., Atkinson, H. J., Beito, T. G., Negron, V., Lingle, W. L., Bruzek, A. K., Hurley, R. M., Wagner, J. M., Flatten, K. S., Peterson, K. L., Schneider, P. A., Larson, M. C., Maurer, M. J., Kalli, K. R., Oberg, A. L., Weroha, S. J., & Kaufmann, S. H. (2021). CHFR and Paclitaxel Sensitivity of Ovarian Cancer. Cancers, 13(23), . https://doi.org/10.3390/cancers13236043
Wahner Hendrickson, Andrea E, et al. "CHFR and Paclitaxel Sensitivity of Ovarian Cancer." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13236043
Wahner Hendrickson AE, Visscher DW, Hou X, Goergen KM, Atkinson HJ, Beito TG, Negron V, Lingle WL, Bruzek AK, Hurley RM, Wagner JM, Flatten KS, Peterson KL, Schneider PA, Larson MC, Maurer MJ, Kalli KR, Oberg AL, Weroha SJ, Kaufmann SH. CHFR and Paclitaxel Sensitivity of Ovarian Cancer. Cancers (Basel). 2021 Nov 30;13(23). doi: 10.3390/cancers13236043. PMID: 34885153.
Copy Download .nbib Format: NLM
Acquired .

Cancer research

Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Ghamsari MRE, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL.
PMID: 34321239
Cancer Res. 2021 Sep 15;81(18):4709-4722. doi: 10.1158/0008-5472.CAN-21-0774. Epub 2021 Jul 28.

In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene

Cite
Nesic K, Kondrashova O, Hurley RM, et al. Acquired . Cancer Res. 2021;81(18):4709-4722doi: 10.1158/0008-5472.CAN-21-0774.
Nesic, K., Kondrashova, O., Hurley, R. M., McGehee, C. D., Vandenberg, C. J., Ho, G. Y., Lieschke, E., Dall, G., Bound, N., Shield-Artin, K., Radke, M., Musafer, A., Chai, Z. Q., Ghamsari, M. R. E., Harrell, M. I., Kee, D., Olesen, I., McNally, O., Traficante, N., Australian Ovarian Cancer Study, DeFazio, A., Bowtell, D. D. L., Swisher, E. M., Weroha, S. J., Nones, K., Waddell, N., Kaufmann, S. H., Dobrovic, A., Wakefield, M. J., & Scott, C. L. (2021). Acquired . Cancer research, 81(18), 4709-4722. https://doi.org/10.1158/0008-5472.CAN-21-0774
Nesic, Ksenija, et al. "Acquired ." Cancer research vol. 81,18 (2021): 4709-4722. doi: https://doi.org/10.1158/0008-5472.CAN-21-0774
Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Ghamsari MRE, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL. Acquired . Cancer Res. 2021 Sep 15;81(18):4709-4722. doi: 10.1158/0008-5472.CAN-21-0774. Epub 2021 Jul 28. PMID: 34321239.
Copy Download .nbib Format: NLM
Regulatory T Cells in Gynecologic Cancer.

MOJ immunology

Ou Y, Cannon MJ, Nakagawa M.
PMID: 30637330
MOJ Immunol. 2018;6(2):34-42. Epub 2018 Mar 16.

Increasing evidence supports that regulatory T cells (Tregs) within the tumor, tumor draining lymph nodes, ascites and peripheral blood of patients with cancer are associated with poor prognosis. Tregs are important mediators of active immune evasion in cancer. In...

Cite
Ou Y, Cannon MJ, Nakagawa M. Regulatory T Cells in Gynecologic Cancer. MOJ Immunol. 2018;6(2):34-42
Ou, Y., Cannon, M. J., & Nakagawa, M. (2018). Regulatory T Cells in Gynecologic Cancer. MOJ immunology, 6(2), 34-42.
Ou, Yang, et al. "Regulatory T Cells in Gynecologic Cancer." MOJ immunology vol. 6,2 (2018): 34-42.
Ou Y, Cannon MJ, Nakagawa M. Regulatory T Cells in Gynecologic Cancer. MOJ Immunol. 2018;6(2):34-42. Epub 2018 Mar 16. PMID: 30637330; PMCID: PMC6329475.
Copy Download .nbib Format: NLM
Amplification of Femtograms of Bacterial DNA Within 3 h Using a Digital Microfluidics Platform for MinION Sequencing.

ACS omega

Liu Y, Jeraldo P, Mendes-Soares H, Masters T, Asangba AE, Nelson H, Patel R, Chia N, Walther-Antonio M.
PMID: 34632220
ACS Omega. 2021 Sep 23;6(39):25642-25651. doi: 10.1021/acsomega.1c03683. eCollection 2021 Oct 05.

Whole genome sequencing is emerging as a promising tool for the untargeted detection of a broad range of microbial species for diagnosis and analysis. However, it is logistically challenging to perform the multistep process from sample preparation to DNA...

Cite
Liu Y, Jeraldo P, Mendes-Soares H, et al. Amplification of Femtograms of Bacterial DNA Within 3 h Using a Digital Microfluidics Platform for MinION Sequencing. ACS Omega. 2021;6(39):25642-25651doi: 10.1021/acsomega.1c03683.
Liu, Y., Jeraldo, P., Mendes-Soares, H., Masters, T., Asangba, A. E., Nelson, H., Patel, R., Chia, N., & Walther-Antonio, M. (2021). Amplification of Femtograms of Bacterial DNA Within 3 h Using a Digital Microfluidics Platform for MinION Sequencing. ACS omega, 6(39), 25642-25651. https://doi.org/10.1021/acsomega.1c03683
Liu, Yuguang, et al. "Amplification of Femtograms of Bacterial DNA Within 3 h Using a Digital Microfluidics Platform for MinION Sequencing." ACS omega vol. 6,39 (2021): 25642-25651. doi: https://doi.org/10.1021/acsomega.1c03683
Liu Y, Jeraldo P, Mendes-Soares H, Masters T, Asangba AE, Nelson H, Patel R, Chia N, Walther-Antonio M. Amplification of Femtograms of Bacterial DNA Within 3 h Using a Digital Microfluidics Platform for MinION Sequencing. ACS Omega. 2021 Sep 23;6(39):25642-25651. doi: 10.1021/acsomega.1c03683. eCollection 2021 Oct 05. PMID: 34632220; PMCID: PMC8495859.
Copy Download .nbib Format: NLM
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.

Cancers

Csizmar CM, Saliba AN, Swisher EM, Kaufmann SH.
PMID: 34945003
Cancers (Basel). 2021 Dec 20;13(24). doi: 10.3390/cancers13246385.

Despite recent discoveries and therapeutic advances in aggressive myeloid neoplasms, there remains a pressing need for improved therapies. For instance, in acute myeloid leukemia (AML), while most patients achieve a complete remission with conventional chemotherapy or the combination of...

Cite
Csizmar CM, Saliba AN, Swisher EM, et al. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246385.
Csizmar, C. M., Saliba, A. N., Swisher, E. M., & Kaufmann, S. H. (2021). PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers, 13(24), . https://doi.org/10.3390/cancers13246385
Csizmar, Clifford M, et al. "PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246385
Csizmar CM, Saliba AN, Swisher EM, Kaufmann SH. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers (Basel). 2021 Dec 20;13(24). doi: 10.3390/cancers13246385. PMID: 34945003.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 65 entries